secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2024-10-04T23:59:59+00:00
Accession:  0001213900-24-085543
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oruka Therapeutics amends CEO & SVP employment agreements, revising severance terms
--------------------------------------------------------------------------------

- CEO Klein: outside CIC, severance = 12 months base salary + 30% time-based equity vesting. Within CIC, 1.5x base+bonus + full equity acceleration.
- SVP Agarwal: outside CIC, 9 months base salary. Within CIC, 0.75x base+bonus + full equity acceleration and 9 months COBRA.
- Agreements also provide full time-based equity acceleration upon death/disability for Klein.
- Base salary ($600K for CEO) and target bonus (50% of base) remain unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000121390024085543/0001213900-24-085543-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000121390024085543/ea0216746-8k_oruka.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-085543

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer